Back to Search
Start Over
COVID‐19, adaptative immune response and metabolic‐associated liver disease.
- Source :
-
Liver International . Nov2021, Vol. 41 Issue 11, p2560-2577. 18p. 1 Diagram, 1 Chart. - Publication Year :
- 2021
-
Abstract
- Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID‐19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low‐grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non‐alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID‐19 can have a worse outcome of COVID‐19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID‐19 complexity and to improve knowledge on its pathophysiology. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14783223
- Volume :
- 41
- Issue :
- 11
- Database :
- Academic Search Index
- Journal :
- Liver International
- Publication Type :
- Academic Journal
- Accession number :
- 153065387
- Full Text :
- https://doi.org/10.1111/liv.15061